Pharma firms valuations do not factor in threats from acceleration in generics adoption in India
The current implied domestic valuations of pharma companies do not adequately factor in threats from any acceleration in the pace of adoption of unbranded and trade generics in India, as per a report by Kotak Institutional Equities.